A daily loss of 0.85 percent doesn’t seem too alarming for the notoriously volatile BioNTech stock. In fact, there have been warning signs in biotech stock prices in recent days that profit hunting may be imminent. The Mainz-based company’s share price last rose from $118.31 to $163.3 on Tuesday. BioNTech’s stock price has now unsuccessfully tried to break the 200-day moving average for three days in a row. Since the beginning of the week, there have been several breaks above the moving average, which is currently at $160.92. However, based on the final course, these differences have not yet been confirmed. Also yesterday: Shares of BioNTech (WKN: A2PSR2, ISIN: US09075V1026, Chart) closed trading at $159.58 on the US technology exchange NASDAQ after hitting an intraday high of $162.03. BioNTech Stock – Fighting for a Major Buy Signal A strong break above the 200 EMA – confirming Tuesday’s intraday high of $163.3 – can still be considered a technical buy signal for BioNTech stock at this point. In the short term, such a price development would make the technical picture of the biotech stock even brighter. Next resistance levels for the biotech stock would then be around $169.95 / $172.75 and the $170.93 / $177.63. The , shares of the Mainz-based company only encompass the $183.27 / $19 .61, which is very important. Another important technical signal for the overall picture of the range is $185.09 / $189.07. Note Support for $152/$15 ! BioNTech shares, on the other hand, now find initial support around $152 / $15 and $150. A recovery from the 200 EMA and a subsequent drop below would be a negative signal for the Mainz-based company’s share price. A similar scenario occurred for BioNTech stock in early August, and it later returned to key support.